Kallikrein and male subfertility. Usefulness of high-unit kallikrein tablets.
We studied the therapeutic effect of long-term oral administration of Kallikrein tablets on male subfertility. Subjects were 26 patients with poor sperm motility and divided into two groups according to the rate of motile spermatozoa: less than 40% (Group A: 9 cases) and 40% or more (Group B: 17 cases). Patients in Group A administered with 600 K.U./day orally for 6 months and those of Group B received 300 K.U./day for initial 3 months and 600 K.U/day for the ensuing 3 months. The changes of semen parameters during the treatment were as follows. a) No increase in sperm count. b) significant improvement of quantitative and qualitative sperm motility. c) Improvement of sperm morphology. d) Significant increase in total number of motile spermatozoa. e) Volume of semen was increased without statistical significance. Testosterone, FSH, and LH levels in blood plasma did not change significantly. The constituents of seminal plasma (fructose, cholesterol, ALP, ACP, GOT and LDH) were determined. Although ACP and GOT showed an increasing tendency and ALP tended to decrease during treatment, we found no biochemical parameter changing parallel with therapeutic results. Eight out of the 26 subjects successfully impregnated their wives (conception rate: 30.8%). No remarkable side effect was detected.
D000284:Administration, Oral; D000328:Adult; D006801:Humans; D007610:Kallikreins / Q000378:metabolism / Q000627:therapeutic use*; D007705:Kinins / Q000378:metabolism; D008297:Male; D009845:Oligospermia / Q000188:drug therapy*; D012661:Semen / Q000378:metabolism; D013076:Sperm Count; D013081:Sperm Motility / Q000187:drug effects
D007705:Kinins; D007610:Kallikreins